Boundless Bio, Inc. Common Stock (BOLD) Stock Price
BOLDStock
$2.83+148.25%52W
Market Cap$64.38M
P/E—
PEG Ratio—
Div yield—
Beta0.67
BOLD Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)129.95%
Price vs S&P 500 (4W)8.58%
VGM Score81.81
BOLD Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.58 | -$1.06 | -82.76%(-$0.48) | |
| Q1 2026 | -$0.56 | -$0.60 | -7.14%(-$0.04) | |
| Q4 2025 | -$0.52 | -$0.58 | -11.54%(-$0.06) | |
| Q3 2025 | -$0.58 | -$0.62 | -6.44%(-$0.04) | |
| Q2 2025 | -$0.65 | -$0.70 | -7.69%(-$0.05) |
BOLD Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
2.29
2.29
2.29
2.17
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BOLDBoundless Bio, Inc. Common Stock | — | — | A | $2.83 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Boundless Bio, Inc. Common Stock
Boundless Bio is a clinical-stage oncology company developing therapeutics that target extrachromosomal DNA (ecDNA), a driver of oncogene amplification in cancer. The company's lead program, BBI-355, is an oral CHK1 inhibitor designed to disrupt ecDNA replication and transcription, addressing an unmet need in patients with oncogene-amplified tumors.